Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to -$3.2 million.

  • NovaBay Pharmaceuticals' Net Cash Flow fell 79237.29% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.2 million, marking a year-over-year decrease of 2826.91%. This contributed to the annual value of -$2.6 million for FY2024, which is 1050.63% down from last year.
  • NovaBay Pharmaceuticals' Net Cash Flow amounted to -$3.2 million in Q3 2025, which was down 79237.29% from -$3.2 million recorded in Q2 2025.
  • NovaBay Pharmaceuticals' 5-year Net Cash Flow high stood at $2.2 million for Q4 2024, and its period low was -$3.2 million during Q2 2025.
  • In the last 5 years, NovaBay Pharmaceuticals' Net Cash Flow had a median value of -$1.3 million in 2021 and averaged -$1.1 million.
  • In the last 5 years, NovaBay Pharmaceuticals' Net Cash Flow tumbled by 175454.55% in 2023 and then soared by 39360.85% in 2024.
  • NovaBay Pharmaceuticals' Net Cash Flow (Quarter) stood at -$1.5 million in 2021, then skyrocketed by 219.82% to $1.8 million in 2022, then crashed by 141.13% to -$751000.0 in 2023, then surged by 393.61% to $2.2 million in 2024, then tumbled by 243.27% to -$3.2 million in 2025.
  • Its Net Cash Flow stands at -$3.2 million for Q3 2025, versus -$3.2 million for Q2 2025 and -$3.0 million for Q1 2025.